Piramal Pharma Share Price Target 2027, 2028 and 2030: Long Term Analyst Forecast

Piramal Pharma at Rs 171.66 owns one of the very few dedicated ADC (antibody-drug-conjugate) manufacturing sites in the world at Grangemouth, Scotland, a scarce, high-margin capability riding the ADC cancer therapy boom. Global pharmaceutical companies including Pfizer, AstraZeneca, and others have been securing CDMO partnerships for ADC manufacturing, and Piramal's Grangemouth facility gives it a structural position in this fast-growing niche. The Piramal Pharma share price target of Rs 245 for 2027, rising to Rs 360 by 2030, anchors to the street consensus while the company is still loss-making.

The Piramal Pharma share price target of Rs 245 for 2027, rising to Rs 360 by 2030, reflects approximately 12% annual earnings growth with a forward multiple consistent with CDMO and Specialty Pharma peers. This article covers the Piramal Pharma share price target 2027, 2028, and 2030 based on FY26 financials and analyst estimates as of August 2026.

Click Here – Get Free Investment Predictions

Piramal Pharma Company Overview

Metric	Details
NSE Ticker	PPLPHARMA
Sector	CDMO and Specialty Pharma
CMP (05 Aug 2026)	Rs 171.66
52-Week High	Rs 250
52-Week Low	Rs 115
Market Cap	Rs 23,599 Cr
FY26 EPS	See rationale
Promoter Holding	35%
12M Consensus	₹244 (+42%)
Piramal Pharma Share Price Target 2027	Rs 245 (+43%)
Piramal Pharma Share Price Target 2028	Rs 280 (+63%)
Piramal Pharma Share Price Target 2030	Rs 360 (+110%)
Bull Case 2030	Rs 461
Bear Case 2030	Rs 274

What most investors miss: Piramal Pharma owns one of the very few dedicated antibody-drug-conjugate (ADC) manufacturing sites globally at Grangemouth, Scotland. ADCs are the fastest-growing oncology drug class globally, and manufacturing capacity is severely constrained. Piramal's early-mover position in ADC CDMO gives it a strategic advantage that should convert into multi-year high-margin contracts as pharma companies scale up their ADC pipelines.

Since the company is still loss-making, we've anchored to the ₹244 street target and rolled it forward assuming approximately14% underlying growth. . The share price targets of Rs 245 for 2027, Rs 280 for 2028, and Rs 360 for 2030 are derived from this earnings trajectory and peer multiples.

Why Is the Piramal Pharma Share Price Target Set at Rs 245 for 2027

ADC Manufacturing at Grangemouth Is a Globally Scarce High-Margin Capability

This is the foundational driver of the Piramal Pharma share price target of Rs 245 for 2027 and Rs 360 by 2030. Since the company is still loss-making, we've anchored to the ₹244 street target and rolled it forward assuming approximately14% underlying growth. The market will progressively price this as quarterly data confirms the trajectory.

CDMO Business Provides Revenue Visibility Through Long-Term Manufacturing Contracts

Investors analysing the Piramal Pharma share price target should track this dimension quarterly, as it provides the clearest signal of whether the compounding thesis is on track. Evidence of sustained improvement in this area is the primary re-rating catalyst for the Piramal Pharma share price target 2028 of Rs 262.

India API and CRAMS Business Provides a Stable Domestic Revenue Base

This structural factor is often underweighted in standard Piramal Pharma share price target analyses, which focus on trailing earnings multiples rather than the competitive positioning embedded in the long-term franchise value. Its persistence through economic cycles is what differentiates the Piramal Pharma share price target 2030 case from a short-term trading call.

Complex Hospital Generics Segment Has High Regulatory Barrier to Entry

For the Piramal Pharma share price target of Rs 360 to materialise by 2030, this factor needs to remain intact and compound over 4 years. Quarterly updates on this metric provide the earliest warning signal of any deviation from the Piramal Pharma share price target base case assumptions.

Path to Profitability by FY27 to FY28 Is the Key Milestone for Re-Rating

As India's economy compounds through 2027 to 2030, this factor provides an additional secular tailwind that is layered on top of the Piramal Pharma-specific earnings growth already embedded in the Rs 245 target for 2027 and the Rs 360 target for 2030.

Piramal Pharma Share Price Targets 2027, 2028 and 2030

Piramal Pharma Share Price Target 2027: Rs 245

The Piramal Pharma share price target 2027 is Rs 245, representing approximately 43 percent upside from CMP Rs 171.66. Since the company is still loss-making, we've anchored to the ₹244 street target and rolled it forward assuming approximately14% underlying growth.. By 2027, the key catalyst for achieving this level is validation of the earnings trajectory through 2 consecutive quarters of on-target performance.

Piramal Pharma Share Price Target 2028: Rs 280

The Piramal Pharma share price target 2028 is Rs 280, implying approximately 63 percent upside from CMP. By 2028, Piramal Pharma should have demonstrated through a full earnings cycle that the approximately 12% growth assumption is sustainable, supporting a re-rating toward the Piramal Pharma share price target 2028 level at a forward multiple consistent with sector peers.

Piramal Pharma Share Price Target 2030: Rs 360

The Piramal Pharma share price target 2030 is Rs 360, implying approximately 110 percent upside from CMP and a 4-year CAGR of approximately 20% from current levels. By 2030, Piramal Pharma should be a mature, well-understood franchise with a track record of consistent compounding that justifies the target multiple.

Bull Case and Bear Case for the Piramal Pharma Share Price Target 2030

Bull Case: Rs 461

The bull case Piramal Pharma share price target of Rs 461 by 2030: Rs 460 by 2030, if the ADC manufacturing contracts scale materially and Grangemouth is expanded, contributing Rs 800 to 1,000 crore annually to EBITDA by FY31, driving a CDMO premium re-rating.

Bear Case: Rs 274

The bear case Piramal Pharma share price target of Rs 274 by 2030: Rs 280 by 2030, if ADC demand concentration with a few large pharma companies creates client concentration risk, Grangemouth faces operational challenges, and the path to profitability extends beyond FY29.

Scenario	Target by 2030	Return	Key Assumption
Bull Case	Rs 461	+169%	Upside scenario with favourable execution and sector conditions
Base Case	Rs 360	+110%	approximately 12% EPS CAGR; peer-multiple sustained through FY31
Bear Case	Rs 274	+60%	Downside scenario with adverse execution or macro headwinds

Key Risks to the Piramal Pharma Share Price Target

USFDA Inspection and Compliance Risk

Any USFDA warning letter or import alert on Piramal Pharma's manufacturing facilities would delay product launches and revenue recognition, directly reducing the earnings trajectory behind the Piramal Pharma share price target. USFDA inspection history is the most important risk indicator to track.

Currency Risk on Export Revenue

Piramal Pharma's international revenue is primarily in US dollars and euros. Any significant INR appreciation against these currencies would reduce the INR value of reported revenues and EPS, compressing the Piramal Pharma share price target earnings assumptions.

Pricing Pressure in Regulated Generic Markets

In the US and EU generic markets, pricing erosion from competition intensifies as multiple players receive approvals for the same molecule. Any acceleration in generic pricing erosion in Piramal Pharma's key export products would compress the Piramal Pharma share price target revenue base.

Clinical Trial and Pipeline Risk

Any setback in Piramal Pharma's clinical trial results or regulatory approvals for pipeline products would delay the revenue ramp from specialty or novel products embedded in the Piramal Pharma share price target 2028 and 2030 assumptions.

How to Invest in Piramal Pharma

Use the Univest Screener to track Piramal Pharma's key financial metrics including EPS growth, margin trends, and analyst upgrades or downgrades in real time. To purchase shares, open a demat account with any SEBI-registered broker and search for NSE ticker PPLPHARMA. Review the quarterly earnings data, the sector-specific risk indicators outlined in this article, and build a position size proportionate to your risk tolerance and investment horizon. Monitor each quarter for the key variables most likely to move the Piramal Pharma share price target. Consult a SEBI-registered financial advisor before making any investment decision.

Use the Univest Screener to Track This Stock Live

Conclusion

The Piramal Pharma share price target of Rs 245 for 2027, Rs 280 for 2028, and Rs 360 for 2030 reflects approximately 12% annual earnings compounding and a forward multiple consistent with CDMO and Specialty Pharma peers. The key drivers and risks are outlined above. Piramal Pharma owns one of the very few dedicated antibody-drug-conjugate (ADC) manufacturing sites globally at Grangemouth, Scotland. ADCs are the fa. For investors with a 3 to 4 year horizon and a tolerance for CDMO and Specialty Pharma-specific risk, the current CMP of Rs 171.66 offers a starting point for building a position aligned to the Piramal Pharma share price target 2030 thesis. Always verify data at NSE and BSE before investing.

Download the Univest iOS App or Univest Android App to track Piramal Pharma share price live and get daily stock recommendations.

Frequently Asked Questions on Piramal Pharma Share Price Target 2027 2028 and 2030

What is the Piramal Pharma share price target for 2027?

Ans. The Piramal Pharma share price target for 2027 is Rs 245, representing approximately 43 percent upside from CMP Rs 171.66 as of August 2026. Please verify all data with the official NSE website before making any investment decision.

What is the Piramal Pharma share price target for 2030?

Ans. The Piramal Pharma share price target for 2030 is Rs 360, implying approximately 110 percent upside from CMP Rs 171.66. This is based on analyst estimates and is not a guaranteed return. Always verify current data at NSE India before investing.

Is Piramal Pharma a good long-term investment?

Ans. Piramal Pharma has a defined analyst consensus that projects earnings compounding through FY31 based on sector-specific growth drivers outlined in this article. Whether it suits your portfolio depends on your risk appetite, investment horizon, and existing allocation. Consult a SEBI-registered financial advisor for personalised guidance.

What do most investors miss about Piramal Pharma?

Ans. Piramal Pharma owns one of the very few dedicated antibody-drug-conjugate (ADC) manufacturing sites in the world (Grangemouth, Scotland) – a scarce, high-margin capability riding the ADC boom (Pfizer-Seagen, AZ-Daiichi deals) that the market underappreciates while the stock optically looks loss-maki

What is the bull case for the Piramal Pharma share price target 2030?

Ans. The bull case Piramal Pharma share price target for 2030 is Rs 461. This requires better-than-base-case execution on the key growth drivers specific to Piramal Pharma's sector, as described in this article. These are analyst projections, not guaranteed returns.

What are the main risks to the Piramal Pharma share price target?

Ans. The key risks to the Piramal Pharma share price target include sector-specific headwinds such as credit cycles (for financial companies), regulatory changes, competitive pressure, and macroeconomic slowdown. Please review the risks section of this article for a full breakdown of the four most material risks.

What is Piramal Pharma's 52-week high and low share price?

Ans. As of August 2026, Piramal Pharma's 52-week high is approximately Rs 250 and the 52-week low is approximately Rs 115. The CMP of Rs 171.66 sits between these levels. Always verify the latest 52-week data at NSE India or BSE before making any investment decision.

How can I buy Piramal Pharma shares?

Ans. You can buy Piramal Pharma shares through any SEBI-registered broker by searching for the NSE ticker PPLPHARMA. Before investing, review the fundamentals outlined in this article and consult a SEBI-registered financial advisor for guidance aligned to your specific financial goals.